Fenspiride

Clinical data
Trade names	Eurespal, Pneumorel
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	R03BX01 (WHO) R03DX03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	90%[1]
Elimination half-life	14–16 hours
Excretion	Urine (90%), feces (~10%)
Identifiers
IUPAC name 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
CAS Number	5053-06-5 Y
PubChem CID	68626
DrugBank	DB08979 N
ChemSpider	3227 N
UNII	S983QC7HKM
KEGG	D07949 Y
ChEMBL	ChEMBL576127 N
CompTox Dashboard (EPA)	DTXSID4023048
ECHA InfoCard	100.023.411
Chemical and physical data
Formula	C15H20N2O2
Molar mass	260.337 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1ccc(cc1)CCN2CCC3(CC2)CN=C(O3)O
InChI InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18) N Key:FVNFBBAOMBJTST-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.^[2] The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.^[3] Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes.^[4] Fenspiride is known to have activity as an alpha-1 blocker, H1 antagonist, it also inhibits PDE3, PDE4, PDE5 with -logIC50 values of 3.44, 4.16, 3.8 respectively.^[5]